Clinical trials: Glioma of Brain
Brain Tumor
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type2.0/2.1 in combination with Doxorubicin therapy for the treatment of DIPG in pediatric…
- Trial name
- NCT05630209
- Testing
- Exablate, Doxorubicin
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- InSightec
Glioma (Any Grade) in the Brain
18F-Floretyrosine Expanded Access Program
The aim of this Expanded Access Program (EAP) is to enable the use of 18F-Floretyrosine with positron emission tomography/computed tomography (PET/CT) or positron emission tomography/magnetic resonance (PET/MR) imaging to…
- Trial name
- NCT06743100
- Testing
- 18F-Floretyrosine
- Where
- 10 sites in United States
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Glioblastoma
A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma
This study is open to adults with newly diagnosed glioblastoma, a type of brain tumor. The study has two parts. Part 1 is open to people who can get their brain tumor removed by surgery.
- Trial name
- NCT05376800
- Testing
- BI 907828 (Brigimadlin)
- Where
- 7 sites in United States, Belgium and 1 more
- Volunteers
- 24 people
- Sponsor
- Boehringer Ingelheim
Primary Brain Tumors, Metastatic Malignant Neoplasm to Brain
Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors
DM-CHOC-PEN is a polychlorinated pyridine cholesteryl carbonate that has demonstrated antineoplastic activities in patients with advanced cancers - melanoma, lung, breast and glioblastoma multiforme (GBM) involving the CNS during…
- Trial name
- DM-CHOC-PEN (NCT02038218)
- Testing
- 4-Demethyl-4-cholestryloxycarbonylpenclomedine
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- DEKK-TEC, Inc.
Advanced Solid Tumor, RAS Mutation
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
This is a Phase 1, First-in-Human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ABM-168 in adult patients…
- Conditions
- Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
- Trial name
- NCT05831995
- Testing
- ABM-168
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- ABM Therapeutics Corporation
Glioma
A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
This study (1438-0003) is open to adults with a tumour in the brain that is positive for the tumour marker delta-like 3 (DLL3). This study is in people with advanced cancer for whom previous treatment was not successful.
- Trial name
- NCT05916313
- Testing
- BI 764532
- Where
- 12 sites in United States, Austria and 4 more
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Recurrent Glioblastoma Multiforme(GBM)
A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme
The current design provides a window to analyze the impact of the ACT001+Pembrolizumab combination on the tumor microenvironment and disease outcomes.
- Trial name
- NCT05053880
- Testing
- ACT001, ACT001 + Pembrolizumab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Accendatech USA Inc.
Brain Edema, Brain Tumor
XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors
The purpose of this study is to compare the safety and efficacy of XERECEPT® to dexamethasone (Decadron) a common treatment for symptoms of brain swelling (edema).
- Trial name
- NCT00088166
- Testing
- hCRF
- Where
- 34 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Celtic Pharma Development Services
Glioblastoma, Small Cell Glioblastoma
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
This 2-arm, randomized, phase III study will investigate the efficacy and safety of the addition of rindopepimut (an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have tumors that express…
- Conditions
- Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma
- Trial name
- ACT IV (NCT01480479)
- Testing
- Rindopepimut (CDX-110) with GM-CSF, Temozolomide, KLH
- Where
- 223 sites in United States, Australia and 22 more
- Volunteers
- 745 people
- Sponsor
- Celldex Therapeutics
Glioblastoma, Diffuse Intrinsic Pontine Glioma
A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas
This is a phase 1/2, uncontrolled, open-label, multicenter study in patients with recurrent and relapsed diffuse intrinsic pontine glioma, glioblastoma, or grade III or IV glioma.
- Trial name
- NCT02750891
- Testing
- DSP-7888
- Where
- 6 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Glioblastoma Multiforme
The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme
The purpose of the PRECISE trial is to determine whether overall survival duration, safety, and quality of life are improved for patients treated with IL13-PE38QQR compared to patients treated with GLIADEL® Wafer following…
- Trial name
- NCT00076986
- Testing
- IL13-PE38QQR, surgery and catheter placement (2 procedures), prolifespan 20 with carmustine implant (GLIADEL® Wafer)
- Where
- 60 sites in United States, Canada and 4 more
- Volunteers
- 300 people
- Sponsor
- INSYS Therapeutics Inc
Glioblastoma, Grade IV Astrocytoma
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
This is a single-arm, open-label, multicenter study in approximately 52 adults with primary (de novo) GB that has recurred or progressed (first or second recurrence, including this recurrence) after treatment(s) including surgery…
- Conditions
- Glioblastoma, Grade IV Astrocytoma, Glioblastoma Multiforme, Grade IV Glioma
- Trial name
- NCT02858895
- Testing
- MDNA55
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- Medicenna Therapeutics, Inc.
Refractory Cancer, Refractory Neoplasm
9-ING-41 in Pediatric Patients With Refractory Malignancies.
9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.
- Conditions
- Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor
- Trial name
- NCT04239092
- Testing
- 9-ING-41, Irinotecan, Temozolomide
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Actuate Therapeutics Inc.
Brain Tumor
Phase I Clinical Study of GB222 to Evaluate the Safety, Tolerability and PK Profiles.
This study is designed to assess the safety and tolerability, pharmacokinetic profiles, immunogenicity of GB222 in Chinese patients with relapsed/progressive high-grade glioma; moreover, changes in cerebral edema, changes in KPS…
- Trial name
- NCT04178057
- Testing
- GB222 3mg/kg, GB222 5mg/kg, GB222 7.5mg/kg
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Genor Biopharma Co., Ltd.
Glioblastoma Multiforme, Astrocytoma
A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511
This is a multicenter, open-label, continuation study to allow subjects who have previously received Toca 511 to continue to receive Toca FC and to allow for extended safety observations.
- Conditions
- Glioblastoma Multiforme, Astrocytoma, Gliomas, Malignant
- Trial name
- NCT04327011
- Testing
- Toca 511 vector, Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine
- Where
- 11 sites in United States
- Volunteers
- 65 people
- Sponsor
- Tocagen Inc.
c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma
The study assessed the safety and the dose of the combination of INC280 and buparlisib (BKM120), as well as the anti-tumor activity of the combination, in patients with recurrent glioblastoma with PTEN mutations, homozygous…
- Trial name
- NCT01870726
- Testing
- INC280, Buparlisib
- Where
- 13 sites in United States, Germany and 3 more
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma, Recurrent Glioblastoma
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
This Phase 2 single arm trial in patients with rGBM will characterize the efficacy, safety, tolerability and initial efficacy of lerapolturev intratumoral infusion followed by intravenous pembrolizumab 14 to 28 days later, and…
- Conditions
- Glioblastoma, Recurrent Glioblastoma, Supratentorial Glioblastoma, Brain Tumor
- Trial name
- NCT04479241
- Testing
- lerapolturev, pembrolizumab
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Istari Oncology, Inc.
High Grade Glioma
Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma
The purpose of this study is to evaluate the impact of Trans Sodium Crocetinate (TSC) on oxygen levels in brain tumor tissue in patients with high grade glioma.
- Trial name
- NCT00826930
- Testing
- Trans Sodium Crocetinate (TSC)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Diffusion Pharmaceuticals Inc
Malignant Glioma, Glioblastoma Multiforme
131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma
This drug is being developed to treat a type of brain cancer, glioma. This study was developed to evaluate the safety, time to disease progression and survival rates after treatment.
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, GBM, Anaplastic Astrocytoma
- Trial name
- NCT00114309
- Testing
- 131-I-TM-601, 131I-TM601
- Where
- 19 sites in United States
- Volunteers
- 66 people
- Sponsor
- TransMolecular
Melanoma, Glioma
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors.
- Conditions
- Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT05538130
- Testing
- PF-07799544, PF-07799933
- Where
- 66 sites in United States, Australia and 5 more
- Volunteers
- 148 people
- Sponsor
- Pfizer